ESR1 and breast cancer: Although HER2+ tumors tend to be more aggressive than other BCs, the prognosis varies depending on the co-expression of hormone receptors (HRs), namely estrogen receptor (ER) and progesterone receptor (PR), and patients with triple-positive BC tumors tend to be younger (≤ 49 years) (3).